Five Below Inc vs GeneDx Holdings Corp — how do they compare? Five Below Inc trades at $200.71 (market cap $10.67B), while GeneDx Holdings Corp trades at $63.66 (market cap $1.96B). The key difference: Five Below Inc is far larger — about 5.4× GeneDx Holdings Corp's market cap, and Five Below Inc is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals.
| FIVE | WGS | |
|---|---|---|
Market Cap | $10.67B | $1.96B |
Sector | Consumer Staples | Technology |
52-Week High | $247.71 | $167.51 |
52-Week Low | $131.94 | $34.51 |
Enterprise Value | $11.56B | $1.96B |
Signals from Pluang's Aura AI — not financial advice
Five Below (FIVE) trades at $193.11, up 0.82% with a bullish technical signal despite mixed moving averages. The company demonstrates strong growth with revenue reaching $3.88 billion in 2025 and consistent earnings beats, including Q1 2026 EPS of $2.22 beating expectations of $1.77. Valuation metrics show a P/E of 24.34 and P/S of 2.11, while profitability remains solid with 8.67% net margin and 21.13% ROE. Recent news highlights store expansion to 2,000 locations and strategic investments in digital marketing.
FIVE presents a compelling growth story with analyst consensus pointing to 33% upside potential to $252.09 target. The stock benefits from strong institutional support (60% buy ratings) and positive earnings momentum, though investors should monitor competitive pressures in value retail and the sustainability of expansion-driven cash flow patterns. Current technical levels show support at $191 with resistance at $194.
GeneDx Holdings Corp. (WGS) trades at $65.785, up 5.37% today, but faces a bearish technical signal with the stock near resistance at $65. The company shows mixed fundamentals with strong revenue growth to $427.54M in 2025 but a net loss of -$21.02M, while analyst consensus remains bullish with a $75.40 price target. Recent news highlights multiple class-action lawsuits alleging securities fraud tied to a 49% stock decline and acquisition underperformance, creating significant investor uncertainty.
The outlook is highly conflicted: strong analyst buy ratings and recent earnings beats contrast with deepening losses, negative cash flow projections for 2026, and legal overhangs. Key risks include litigation outcomes, profitability challenges, and execution missteps, but the stock offers potential upside if the company can stabilize margins and resolve legal issues amid high institutional skepticism.
Trailing returns across standard periods
Five Below is a value-oriented retailer that operated 1,190 stores in the United States as of the end of fiscal 2021. Catering to teen and preteen consumers, stores feature a wide variety of merchandise, the vast majority of which is priced below $6. The assortment focuses on discretionary items in several categories, particularly leisure (such as sporting goods, toys, and electronics
Read more on FIVE →GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →